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To evaluate the survival benefit of gemcitabine and paclitaxel (GT) chemotherapy for 
patients with metastatic urothelial cancer (UC), retrospective analysis was performed 
to compare overall survival in two periods, before (Group I) and after (Group II) the 
introduction of GT chemotherapy. 
Patients and methods  
Eighty-five patients with metastatic UC were treated with MEC/MVAC (methotrexate, 
epirubicin and cisplatin/ methotrexate, vinblastine, doxorubicin and cisplatin) or GT 
between 1995 and 2007. The response rate, maintenance rate, maintenance duration of 
each regimen, and the survival time of responding patients in each group were 
evaluated retrospectively. 
Results 
The median survival of patients in Group ΙI (20 months) was significantly longer than 
Group I (13 months) (p = 0.03). Especially in patients with a favorable response 
(CR/PR) to induction chemotherapy, the median survival period was significantly 
different between Group Ι and Group II (median 15 months and 28 months, 
respectively; p = 0.02). The rate of the shift to maintenance chemotherapy when using 
GT chemotherapy was significantly higher than with MEC/MVAC chemotherapy 
alone (p < 0.05), and the cessation rate due to adverse effects was significantly lower 




Our results demonstrated that the administration of GT chemotherapy may be useful 
to improve the survival of patients with metastatic UC. This effect was significant, 
especially among those who were sensitive to the induction course of first-line 
chemotherapy. The excellent tolerability of GT regimens may be suitable for 
maintenance chemotherapy.  
 
Mini-abstract 
The combination chemotherapy of gemcitabine and paclitaxel showing excellent 
tolerability and comparable efficacy to MVAC may be beneficial to improve the 
survival of patients with metastatic urothelial carcinoma. 
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Metastatic urothelial cancer (UC) is rarely curable and the prognosis is still poor. 
It has been two decades since Sternberg et al. investigated the MVAC (methotrexate, 
vincristine, doxorubicin, cisplatin) regimen and demonstrated a markedly objective 
response to combination chemotherapy in 19851; however, MVAC only achieved 
short a response duration and low progression-free survival rate in long-term 
follow-up trials2,3. Moreover, the MVAC regimen causes considerable adverse effects, 
including myelosuppression, nephrotoxicity, mucositis and neuropathy, and even 
treatment-related death2,4,5. These toxicities make it difficult to apply MVAC as 
long-term maintenance chemotherapy or for patients with renal insufficiency or other 
coexistent clinical disorders. Several new regimens have been developed by 
modifying MVAC, such as MEC (methotrexate, epirubicin and cisplatin) or MVEC 
(methotrexate, vincristine, epirubicin and cisplatin), which have been demonstrated to 
have similar efficacy to MVAC6; however, these regimens have similar drawbacks to 
MVAC chemotherapy. Therefore, it has been an urgent issue to develop novel 
substitute regimens for metastatic UC to overcome the limitations of MVAC. 
In recent years, new representative chemotherapeutic agents, such as gemcitabine 
and taxanes, have been developed7,8. Especially in the 2000s, the combination of 
gemcitabine and paclitaxel (GT) was further developed as second-line chemotherapy, 
which had comparable efficacy to MVAC and fewer adverse effects9,10. Further, the 
GT regimen also has the advantage of being suitable even for CDDP-unfit patients, 
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such as those with renal insufficiency or a poor performance status. Several clinical 
trials have demonstrated that the GT regimen offers an encouraging alternative and 
promising second-line treatment option for patients with prior cisplatin-based 
chemotherapy with high response rates and low toxicity8-13; however, it has not been 
fully elucidated whether administration of the GT regimen can extend the overall 
survival of patients with metastatic UC. 
Our institute adopted the MEC/MVAC regimen as first-line chemotherapy for 
metastatic UC in the 1990s and then started to use the GT regimen as second-line 
chemotherapy or chemotherapy for CDDP-unfit patients in 2001. In the present study, 
we retrospectively analyzed overall survival in the two periods of 1995-2000 and 
2001-2007 to evaluate whether the induction of GT chemotherapy was beneficial to 




Patients and methods    
 
Patient characteristics 
 Eighty-five patients with pathologically confirmed metastatic UC, who were 
treated by MEC/MVAC or GT between 1995 and 2007 at Kyoto University Hospital, 
were enrolled in this study (Table 1). These patients were divided into two groups: 
Group I: 1995-2000 and Group II: 2001-2007 because we started GT chemotherapy as 
second-line chemotherapy or chemotherapy for CDDP-unfit patients in 2001. No 
chemotherapy was given within 4 weeks before the study was initiated. Patients were 
required to have an adequate bone marrow reserve (platelet count >100,000/μl, white 
blood cell (WBC) count >3000/μl, hemoglobin level >10 g/dl) and normal hepatic 
function (serum bilirubin <1.5 mg/dl). Additional requirements for the MEC/MVAC 
regimen included normal renal function (pretreatment creatinine clearance >50 
ml/min). On the other hand, the GT regimen could be adapted regardless of renal 
impairment, although the dose was reduced to 50-80% for a serum creatinine level >2 
mg/ml or ECOG performance status >2. During these periods, GC (gemcitabine + 
cisplatin) chemotherapy was not administered in our institute. All patients who were 
enrolled in this study signed a written informed consent form. All of the procedures 
followed were in accordance with the ethical standards of the Institutional Review 
Board at the Kyoto University Graduate School of Medicine and the Declaration of 





 For the MVAC regimen, methotrexate 30 mg/m2 on days 1, 15, and 22, 
vinblastine 3 mg/m2 on days 2, 15, and 22, doxorubicin 30 mg/m2 on day 2, and 
cisplatin 70 mg/m2 on day 2 were administered intravenously every 4 weeks. For the 
MEC regimen, methotrexate 30 mg/m2 on day 1, epirubicin 50 mg/m2 on day 1, and 
cisplatin 50 mg/m2 on days 2 and 3 were given intravenously every 4 weeks. For the 
GT regimen, gemcitabine 2500 mg/m2 and paclitaxel 150 mg/m2 on day 1 were 
infused intravenously every 2 weeks. From 1995 to 2000, MEC/MVAC was adopted 
as the standard chemotherapy regimen for patients with metastatic UC. Since 2001, 
MEC/MVAC has been used as the first-line chemotherapy, and GT as second-line 
chemotherapy or for CDDP-unfit cases. After the initial one to two cycles of first-line 
chemotherapy, defined as induction chemotherapy in this study, the response was 
assessed by CT scan. If progressive disease (PD) was seen, defined as an increase 
>25% in the size of measurable lesions or the development of any new lesions, the 
chemotherapy was ceased, followed by the best supportive care (BSC) or other 
chemotherapy regimens. If the response was stable disease (SD) or favorable (partial 
response (PR) or complete response (CR)), the same regimens were continued until 
disease progression or severe toxicity was observed, or patients asked to cease the 
treatment. Maintenance chemotherapy was defined as 3 or more cycles of 
administration of the same regimen. When disease progression or severe toxicity was 
observed in maintenance chemotherapy, the chemotherapy was ceased, followed by 
the best supportive care or other chemotherapy regimens, as well as in the case of 
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induction chemotherapy. For some responding cases, dosage and intervals were 
changed appropriately, so as to use the optimal dosage and intervals of drug 
administration. 
 The response rate, maintenance rate, maintenance duration of each regimen, and 
the survival time of responding patients in each group were evaluated retrospectively. 
Kaplan-Meier survival curve showed the data within 60 months because of the 
difference of observation periods between two groups. 
 
Response criteria 
 Tumor size and new lesions were measured on CT scan at baseline and after each 
two cycles of chemotherapy or as clinically indicated. Responses were evaluated by 
the New Response Evaluation Criteria in Solid Tumors: Revised RECIST guideline 
(version 1.1)14. The non-parametric Mann-Whitney U-test was used to compare 
groups. The duration of survival was calculated from the initiation of first-line 
chemotherapy to the date of death or to the last follow-up. Survival rates curves were 
constructed using the Kaplan–Meier method. The log-rank test was performed to test 
associations between chemotherapy and survival. A p value <0.05 was considered 
significant. Toxicity grade was defined according to the National Cancer Institute 






1. Response  
The patient characteristics are shown in Table 1. From 1995 to 2007, 85 patients 
with metastatic UC were enrolled in this study; 37 and 48 patients were enrolled in 
Group I (1995-2000) and Group II (2001-2007), respectively. There was no 
significant difference in patients’ background, such as age, status of primary focus, 
perioperative chemotherapy and metastatic sites between Group I and Group II. The 
37 patients in Group I were treated with MEC/MVAC as first-line chemotherapy, 
although 14 patients received several kinds of perioperative chemotherapy, consisting 
of MEC, MVAC, CISCA, transarterial infusion of CDDP and doxorubicin for 6, 3, 4 
and 1 patient, respectively. On the other hand, 30 patients in Group II were treated 
with MEC/MVAC as first-line chemotherapy and 18 were treated with GT as first-line 
chemotherapy because of a CDDP-unfit status (n=5) or a history of perioperative 
MEC/MVAC chemotherapy (n=13). As second-line chemotherapy, 16 patients 
received GT chemotherapy after MEC/MVAC chemotherapy.  
Response rate of chemotherapy is shown in Table2. Favorable response rates 
(CR or PR) with the MEC/MVAC regimen were 51.4 % in Group I and 63.3% in 
Group II, respectively. In Group II, first-line GT chemotherapy showed a 61.1% 
favorable response rate. Among these patients, 7 (53.8%) of 13 patients with 
perioperative chemotherapy and 4 (80.0%) of 5 CDDP-unfit patients achieved CR or 
PR. Overall, there was no difference in the response rate to first-line chemotherapy 
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between Group I and Group II (51.4% vs. 62.5%, respectively: p = 0.9409). Clinical 
courses in Group II are described in Figure 2. There was a second-line GT 
chemotherapy for patients treated with MEC/MVAC in Group II, but no standard 
regimen for second-line treatment in Group I existed. Although most patients with 
progressive disease after MEC/MVAC shifted to BSC, 5 continued 1 to 3 cycles of 
other regimens despite poor response. Among them, two patients received TIP 
(paclitaxel, ifosfamide and CDDP), other two received transarterial infusion of CDDP 
(and doxorubicin) for liver metastasis, and another received CISCA.  
The response rate with second-line GT in Group II was 18.8% overall. When 
the chemotherapy regimen was changed because of a poor response to first-line 
MEC/MVAC (MEC/MVAC refractory case), no favorable response was achieved, 
whereas 3 of 5 (60%) patients who ceased first-line MEC/MVAC because of severe 
adverse effects (MEC/MVAC-sensitive cases) showed a favorable response to GT (p 
< 0.05). 
 
2. Survival time  
 Overall survival was examined in Group I and II (Fig. 1a). The median survival 
period of patients in Group ΙI (20 months, 95% confidence interval [CI] 14-29 
months) was significantly longer than in Group I (13 months, 
95% confidence interval [CI] 10-16 months) (p = 0.03).  
 The median survival period of SD/PD patients in Group Ι was 9 (95% [CI] 6–11) 
months, which did not significantly differ from that of SD/PD patients in Group II 
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(median 10, 95% [CI] 8–19 months; p = 0.8), indicating that the administration of GT 
chemotherapy did not contribute to the improvement of survival of patients with a 
poor response (SD/PD) to induction chemotherapy. On the other hand, among patients 
with a favorable response (CR/PR) to induction chemotherapy, the median survival 
period was significantly different between Group Ι and Group II (median 15 
(95% [CI] 12–17) months and 28 (95% [CI] 19–48) months, respectively; p = 0.02). 
These results indicate that the administration of GT chemotherapy might contribute to 
the improved survival of chemotherapy-sensitive patients (Fig. 1b, c).  
 
3. How to continue chemotherapy for PR/CR cases 
 Based on the above results that the survival of patients with a favorable response 
(CR/PR) to induction chemotherapy was improved in Group II, the differences in 
overall treatment for those patients in the two groups were examined (Table 3). 
 Among 19 CR/PR cases in Group Ι, although 15 patients (78.9%) could shift to 
maintenance MEC/MVAC, 8 patients (42.1%) had to cease chemotherapy because of 
severe adverse effects. The average of the total cycles of chemotherapy was 4.5 cycles 
(2-14 cycles). In Group II, 19 patients showed CR/PR with induction MEC/MVAC 
chemotherapy. Twelve received second-line GT chemotherapy, 11 of whom (91.7%) 
could shift to maintenance chemotherapy. The average of the total cycles of 
chemotherapy for those patients was 7.2 cycles (2-14 cycles). Moreover, 11 of 18 
patients who received first-line GT chemotherapy achieved CR/PR and 10 (90.9%) 
could shift to maintenance chemotherapy, resulting in 5.5 cycles of chemotherapy 
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(1-9 cycles). These results indicate that the rate of the shift to maintenance 
chemotherapy when using GT chemotherapy was significantly higher than with 
MEC/MVAC chemotherapy alone (p < 0.05). Further, the cessation rate due to 
adverse effects was significantly lower when using GT chemotherapy (26.1%) than 
MEC/MVAC in Group Ι (42.1%). This less toxic aspect of GT chemotherapy may 
contribute to the high maintenance rate and longer survival period in favorable 
responders. Finally, frequencies of adverse events are shown in Table 4. Neutropenia 
was the most common serious toxicity observed in 21 patients (61%) but grade 4 
neutropenia was observed only in one patient (3%). Bleeding episodes or anemia was 
not observed. Among non-hematological toxicity, neuralgia and myalgia were the 
most common toxicities observed in 12 patients (35%), respectively. All were Grade 1 
or 2 and controlled by NSAIDs or Chinese herb, but long-lasting symptoms caused 
treatment cessation in some patients. Three patients had interstitial pneumonitis (IP) 
possibly attributed to gemcitabine in the initial experience, but later no IP was 




 Our institute adopted the MEC/MVAC regimen as first-line chemotherapy for 
metastatic UC in the 1990s and then started to use GT regimen as second-line 
chemotherapy or chemotherapy for CDDP-unfit patients in 2001. This retrospective 
outcome study demonstrated that the GT regimen was as effective as MEC/MVAC, 
except for MEC/MVAC refractory cases. Furthermore, comparison of the overall 
survival suggested that introduction of the GT regimen may contribute to the 
improved survival of patients with metastatic UC, especially patients with a favorable 
response to induction chemotherapy in first-line chemotherapy, while MEC/MVAC 
chemotherapy is still an appropriate regimen for those who can tolerate such intensive 
chemotherapy. 
 First-line MEC/MVAC chemotherapy showed an initial response rate of 50–70%, 
but only achieved a short response duration and low progression-free survival rate in 
long-term follow-up trials2,3. Moreover, the MVAC regimen caused multiple adverse 
effects, including myelosuppression, nephrotoxicity, mucositis and neuropathy, and 
even treatment-related death, and the overall survival of patients with metastatic 
urothelial cancer is still approximately 10% after 2 years. Patients with renal 
insufficiency or a poor performance status are not suitable for these 
cisplatin-containing regimens and, further, an effective and safe regimen against 
cisplatin refractory cancer is required as second-line chemotherapy. Several reports 
have demonstrated the effectiveness of carboplatin instead of cisplatin for these 
patients, but the efficacy of carboplatin is still controversial when compared with 
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cisplatin15,16. As other candidates, combination regimens of new agents without 
cisplatin have been investigated, such as gemcitabine and epirubicin, or gemcitabine 
and docetaxel, but the response rate of these regimens was not superior to that of GT 
chemotherapy17-19. Previous trials assessing GT chemotherapy have demonstrated a 
variable response rate of 38–69%8-13. Our results demonstrating an overall response 
rate to GT chemotherapy of 41% (14 of 34 patients) are compatible with previous 
results. In detail, first-line GT chemotherapy was effective for 61% of patients, a 
similar response rate to previous MEC/MVAC chemotherapy. In particular, the high 
response rate (80%) of CDDP-unfit patients may indicate that the GT regimen is a 
promising regimen for these patients. As second-line chemotherapy, the favorable 
response rate was 0% and 60% in MEC/MVAC refractory patients and sensitive 
patients, respectively, although 45% of MEC/MVAC refractory patients achieved 
stable disease with GT. As recent reports suggested that there may be some correlation 
between the response to first-line MEC/MVAC and the response to second-line 
GT12,13, we think that chemoresistant characteristics both against GT and 
MEC/MVAC may originate from a genetic or epigenetic background in bladder 
cancer, and that novel molecular target therapies based on DNA microarray or 
proteomics are necessary to overcome this problem.  
Because most previous reports regarding GT chemotherapy showed an overall 
response rate to GT chemotherapy but did not describe the survival benefit of this 
regimen8-13, we think that the important finding of our study is that the introduction of 
combination chemotherapy of gemcitabine and paclitaxel may be beneficial to extend 
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the survival of patients with a favorable response to induction chemotherapy in 
first-line chemotherapy. Our results showed that the median survival of 
chemosensitive patients was significantly improved after introduction of the GT 
regimen. One of the most important reasons may be the less toxic aspect of the GT 
regimen, because GT could be adopted for 5 CDDP-unfit patients, 4 of whom 
achieved a favorable response and, further, because the cessation rate due to adverse 
effects was significantly lower when using GT chemotherapy (26.1%) in Group II 
than MEC/MVAC in Group Ι (42.1%). We reported the initial experience of GT 
chemotherapy in our institute previously, showing no grade 3 gastrointestinal or 
neuronal side effects, although 26% of patients had grade 3 myelosuppression and 4% 
had grade 3 interstitial pneumonitis20. After the first report, we eventually did not see 
any more discontinuance of GT chemotherapy because of severe toxicity. We think 
that patient selection is important to prevent severe interstitial pneumonia, but the GT 
regimen is advantageous to continue maintenance chemotherapy because of its 
excellent tolerability as first-line chemotherapy for CDDP-unfit patients and as 
second-line chemotherapy for CDDP-treated patients.  
 The limitation of this study is that data were collected retrospectively from 
different periods and includes only a small number of patients. The dosage and 
intervals were changed appropriately to use the optimal settings. From the results that 
response rate with PR/CR of MEC/MVAC therapy in group II (63.3%) is higher than 
that in group I (51.4%), improvement of survival may be influenced by other factors 
including development of supportive care such as bisphosphonate or appropriate 
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radiation therapy. Further, 12 patients treated with MEC/MVAC in group II could not receive 
second-line GT chemotherapy because of acute disease progression, severe adverse effect after 
multiple cycles of MEC/MVAC, although 7 of 12 patients showed the good initial response to 
MEC/MVAC. We think that it is important in the future prospective study to clarify the criteria to 
shift from first-line to second-line chemotherapy to show the benefit of second-line GT 
chemotherapy, because less-toxic maintenance GT regimen possibly show its benefit especially to 
MEC/MVAC sensitive patients. Metastatic sites may have an influence on the response 
and survival rate after chemotherapy, although our previous report showed that there 
was no significant difference in response rate to GT chemotherapy20. To clarify the 
effect of GT chemotherapy, a multi-institutional prospective and randomized trial is 
warranted. Recently, GC chemotherapy has become the standard first-line 
chemotherapy instead of MEC/MVAC chemotherapy after reports of randomized 
trials21,22. GC chemotherapy is also recommended as first-line chemotherapy in the 
Japanese guideline for invasive bladder cancer23, and we changed our first-line 
chemotherapy from MEC/MVAC to GC in 2008. GC chemotherapy is less toxic and 
can be continued for more cycles than MEC/MVAC (commonly continued for 6 
cycles as induction chemotherapy); however, because the efficacy of GC 
chemotherapy is not superior to MEC/MVAC, and its adoption for CDDP-unfit 
patients is still difficult, we think that it may be important and meaningful to elucidate 





 Our results demonstrated that the administration of GT chemotherapy may be 
useful to improve the survival of patients with advanced or metastatic urothelial 
cancer. This effect was significant, especially among those who were sensitive to 
induction courses of first-line chemotherapy. The excellent tolerability of the GT 
regimen may be advantageous as maintenance chemotherapy. Prospective exploration 
of the optimal dosage or intervals of GT administration, which can maximally prolong 
the survival time, are warranted.  
 




Figure 1. Overall survival rate of all patients in Group I (red line) and Group II (blue 
line)(1a). Overall survival rate of poor responders (SD/PD) to induction 
chemotherapy (1b) and favorable responders (CR/PR) (1c). 
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No. of patients  37 48
Gender (male ； female) 27；10 35；13 >0.9999
Age 63 (46-84) 66 (37-79) 0.1055
Primary focus
　Location (bladder ；renal pelvis and ureter) 16；24 29；26 0.2983
　Depth of invasion (pTa；1；2；3；4；X) 4；7；5；11；7；6 2；9；10；21；11；2 0.2703
　Operation before chemotherapy 15；17 20；26 0.8195
　　(total cystectomy; nephroureterectomy)
Perioperative chemotherapy 14 18 >0.9999
Metastasis
　lymph nodes；lung 20；16 25；21 0.7797
　bone；liver；others 8；4；5 14；11；7
      Group I
(1995-2000)
      Group II
(2001-2007)
p  value





n PR/CR SD PD
" perioperative MEC/MVAC " 13 7 (53.8%) 2 4
" CDDP-unfit " 5 4 (80.0%) 0 1
second-line GT 16 3 (18.8%) 6 7
" MEC/MVAC refractory " 11 0 5 6






* The response was assessed by CT scan after the 2 initial courses of chemotherapy
 MEC/MVAC 37 12
   Group I       
(1995-2000)
 MEC/MVAC 30
   Group II      
(2001-2007)
first-line GT 18








MEC/MVAC → GT 12 11 (91.7%) 5 4 30
 3.4 (1-5)
→       4.0
(1-13)
0 2









    Group II
(2001-2007)




    Group I
(1995-2000)













Toxicity Grade 1-2 (%) Grade 3-4(%)
Neutropenia 29 32




Interstitial pneumonia 9 3
(% of patients)
Table 4. Adverse effect of GT regimen (NCI-CTC grade) 
 


